Clinical trials: Pituitary Diseases
Atopic Dermatitis
Cutivate Lotion HPA Axis Pediatric Study
A multi-center, open-label, Phase IV, unblinded study using Cutivate (fluticasone propionate, 0.05%)lotion and it's possible effects on the HPA axis of infants diagnosed with atopic dermatitis.
- Trial name
- NCT00546000
- Testing
- Fluticasone propionate 0.05% lotion
- Where
- 10 sites in United States
- Volunteers
- 56 people
- Sponsor
- Fougera Pharmaceuticals Inc.
Cushing Syndrome
A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome
This is a Phase 3, double-blind, placebo-controlled, randomized-withdrawal study to assess the efficacy, safety and pharmacokinetics (PK) of relacorilant in patients with endogenous Cushing syndrome and concurrent type 2 diabetes…
- Trial name
- GRACE (NCT03697109)
- Testing
- Relacorilant
- Where
- 64 sites in United States, Austria and 9 more
- Volunteers
- 152 people
- Sponsor
- Corcept Therapeutics
Hyponatremia, Syndrome of Inappropriate ADH (SIADH) Secretion
An Observational Study Measuring Outcomes in Cancer Patients Treated for Moderate to Severe Hyponatremia in Italy
This observational, prospective, non-interventional study will include cancer patients who need a treatment for hyponatraemia secondary to SIADH.
- Conditions
- Hyponatremia, Syndrome of Inappropriate ADH (SIADH) Secretion, Cancer
- Trial name
- ASSERT (NCT02573077)
- Where
- 20 sites in Italy
- Volunteers
- 69 people
- Sponsor
- Otsuka Pharmaceutical Europe Ltd
Acromegaly
Canadian Pegvisomant Compassionate Study In Acromegalic Patients
The purposes of this study are: 1) to provide SOMAVERT for compassionate use to patients with acromegaly or who have completed clinical trials and were responsive, and 2) to evaluate the safety and tolerability of SOMAVERT.
- Trial name
- NCT00151437
- Testing
- Pegvisomant treatment, Medical History, demographics, Sign and symptoms: questionnaire
- Where
- 5 sites in Canada
- Volunteers
- 30 people
- Sponsor
- Pfizer
Growth Hormone Deficiency
IGF1 Generation Test
To assess the predictive value of the short term IGF-1 stimulation test, based on IGF-1 changes, on the 24 months growth response to 2 different doses of GH in patients with conventional GH deficiency.
- Trial name
- CAREL (NCT00145457)
- Testing
- Blood sample, Radiography
- Where
- 8 sites in France
- Volunteers
- 82 people
- Sponsor
- Pfizer
Hyponatremia, Syndrome of Inappropriate ADH (SIADH) Secretion
An Observational Study on Real-world Use and Outcomes of Patients Treated With Tolvaptan for Hyponatraemia Due to SIADH
This is a retrospective chart review non-interventional study designed to collect real world data on the use and outcomes of tolvaptan for the treatment of patients with hyponatraemia secondary to syndrome of inappropriate…
- Trial name
- SAMPLE (NCT02545101)
- Where
- 7 sites in Germany, Spain
- Volunteers
- 100 people
- Sponsor
- Otsuka Pharmaceutical Europe Ltd
Adult Growth Hormone Deficiency (AGHD)
Open-label Extension Study to Evaluate the Safety of Long-term Twice-monthly Administration of Somavaratan in Adult Growth Hormone Deficiency (AGHD)
Open-label extension study to evaluate the safety of long-term twice-monthly administration of somavaratan in adults with Growth Hormone Deficiency (GHD).
- Trial name
- NCT02719990
- Testing
- somavaratan
- Volunteers
- 36 people
- Sponsor
- Versartis Inc.
Rhinitis, Allergic, Perennial
A Study of GW685698X for the Treatment Of Perennial Allergic Rhinitis in Adolescents and Adults
The purpose of this study is to assess the effect of an aqueous nasal spray investigational compound compared to placebo on the hypothalamic pituitary adrenocortical (HPA) axis system in adolescents and adults 12 to 65 years of…
- Trial name
- NCT00116818
- Testing
- GW685698X aqueous nasal spray
- Where
- 2 sites in United States, Canada
- Volunteers
- 90 people
- Sponsor
- GlaxoSmithKline
Acromegaly
A Study to Evaluate the Risk of Developing a Heart Condition Called Valvular Regurgitation in Patients With Acromegaly Treated With Either Lanreotide or Octreotide
The aim of the study is to compare the risk of acromegaly patients developing valvular regurgitation when receiving lanreotide or octreotide
- Trial name
- NCT00234520
- Where
- 33 sites in Belgium, Czechia and 8 more
- Volunteers
- 225 people
- Sponsor
- Ipsen
Perennial Allergic Rhinitis
Study of the Effects of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol on Hypothalamic-Pituitary-Adrenal (HPA) Axis
To demonstrate the effects of ciclesonide applied as a nasal aerosol and ciclesonide aqueous (AQ) nasal spray on hypothalamic-pituitary-adrenal axis.
- Trial name
- NCT01033825
- Testing
- Ciclesonide HFA Nasal Aerosol 320 mcg, Ciclesonide HFA Nasal Aerosol 160 mcg, Ciclesonide Aqueous Nasal Spray 200 mcg
- Where
- 6 sites in United States
- Volunteers
- 310 people
- Sponsor
- Sumitomo Pharma America, Inc.
Acromegaly
A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs
The primary purpose of this study is to assess the effect of Debio 4126 in the maintenance of the levels of insulin-like growth factor 1 (IGF-1) ≤1x upper limit of normal (ULN) in the double-blind period (Period 1) in comparison…
- Trial name
- OXTEND™-03 (NCT06930625)
- Testing
- Debio 4126
- Where
- 74 sites in United States, Austria and 19 more
- Volunteers
- 119 people
- Sponsor
- Debiopharm International SA
Growth Hormone Deficiency
A Long-Term Safety Trial of LUM-201 in Children With Idiopathic Growth Hormone Deficiency Who Have Previously Completed a LUM-201 Clinical Trial (OraGrowtH211)
This is a multi-national trial. The trial aims to study the long-term safety of LUM-201 in subjects with Idiopathic Pediatric Growth Hormone Deficiency (iPGHD).
- Trial name
- OraGrowtH211 (NCT05796440)
- Testing
- LUM-201
- Where
- 7 sites in United States, Australia
- Volunteers
- 60 people
- Sponsor
- Lumos Pharma
Growth Hormone Deficiency
Safety, Tolerability and Efficacy of Weekly TV-1106 in Adults With Growth Hormone Deficiency
The primary objective of this study is to evaluate the clinical effect of TV-1106.
- Trial name
- NCT01811576
- Testing
- TV-1106, Recombinant human growth hormone
- Where
- 23 sites in United States, Czechia and 7 more
- Volunteers
- 52 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
GHD
A Study to Investigate Efficacy and Safety of Weekly PEG-somatropin (GenSci004) in Treatment Naive Children With Growth Hormone Deficiency
The purpose of this study is to evaluate the efficacy and safety of weekly GenSci004 compared with daily Genotropin in treatment-naive children with growth failure due to GHD.
- Trial name
- ELEVATE (NCT06007417)
- Testing
- GenSci004, Genotropin
- Where
- United States
- Volunteers
- 162 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Hyponatremia, Dilutional Hyponatremia
Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia
The purpose of this study is to determine if hospitalized patients with symptomatic hyponatremia treated with tolvaptan are in the hospital for less time than patients treated with fluid restriction.
- Conditions
- Hyponatremia, Dilutional Hyponatremia, Inappropriate ADH Syndrome
- Trial name
- SALACIA (NCT01227512)
- Testing
- tolvaptan, Fluid Restriction
- Where
- 56 sites in United States
- Volunteers
- 124 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Cushings Disease, Cushing Disease
Safety and Efficacy of LCI699 in Cushing's Disease Patients
This exploratory study is a proof of concept study to determine whether LCI699 can safely reduce the level of urinary free cortisol in patients with Cushing's disease.
- Trial name
- NCT01331239
- Testing
- LCI699
- Where
- 10 sites in United States, France and 2 more
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
Growth Hormone Deficiency, Turner Syndrome
Long-term Safety and Effectiveness of Growth Hormone With GHD, TS, CRF, SGA , ISS and PWS in Children
The purpose of this study is to evaluate the long-term safety and effectiveness of growth hormone (Eutropin Inj./Eutropin plus Inj.) treatment with GHD (Growth Hormone Deficiency), TS (Turner Syndrome),CRF (Chronic Renal…
- Conditions
- Growth Hormone Deficiency, Turner Syndrome, Chronic Renal Failure, Small for Gestational Age
- Trial name
- LGS (NCT01604395)
- Where
- South Korea
- Volunteers
- 6,000 people
- Sponsor
- LG Chem
Acromegaly
Single Dose Pharmacology Study of DG3173 and Octreotide in Acromegalic Patients.
The study is designed to investigate the safety, tolerability and efficacy of DG3173 in untreated acromegaly patients. Twenty patients received ascending single doses of DG3173 and one dose of octreotide, the current gold…
- Trial name
- NCT02235987
- Testing
- octreotide, DG3173
- Volunteers
- 20 people
- Sponsor
- Aspireo Pharmaceuticals Limited
Growth Hormone Deficiency
A Prospective Non-Interventional Study Protocol With Primary Data Collection - Assessment Of The Long Term Treatment Outcomes Of Genotropin Treatment In Growth Hormone Deficiency (GHD) Patients
The purpose of this study is to assess the long term treatment outcomes of Growth Hormone treatment in patients who are prescribed and treated with Genotropin.
- Trial name
- NCT01947894
- Testing
- Non Interventional Study
- Where
- 12 sites in Sweden
- Volunteers
- 377 people
- Sponsor
- Pfizer
Cushing's Disease
A Trial of Lu AG13909 in Adult Participants With Cushing's Disease
This trial will evaluate the effects of Lu AG13909 in adult participants with Cushing's disease (CD). CD is a rare and serious disorder where the body makes too much of a hormone called cortisol.
- Trial name
- BalanCeD (NCT06471829)
- Testing
- Lu AG13909
- Where
- 27 sites in United States, France and 7 more
- Volunteers
- 16 people
- Sponsor
- H. Lundbeck A/S